Physician profile
Robert J Ondash
NPI 1053320069
$8,355.32
in general payments reported to CMS, 2019-2025
49 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,763 · 2020: $1,043 · 2021: $920 · 2022: $534 · 2023: $1,260 · 2024: $1,510 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,094.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $976.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $895.24 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $784.99 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $632.75 | 2019-2025 | |
| Lilly USA, LLC | $620.60 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $578.62 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $445.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $356.69 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $276.74 | 2019-2021 | |
| Allergan, INC. | $250.10 | 2019-2020 | |
| Abbott Laboratories | $211.68 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $197.32 | 2019-2023 | Veozah |
| Antares Pharma, INC. | $170.35 | 2020-2025 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $159.25 | 2019-2024 | Livalo |
| Gilead Sciences, INC. | $151.55 | 2019-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ondash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.